Business Wire

ANT-GROUP

31.5.2022 08:34:04 CEST | Business Wire | Press release

Share
Ant Group Appointed by Elevandi as Advisory Committee Member

Ant Group has been appointed as a member on the advisory committee of Elevandi, a company set up by the Monetary Authority of Singapore (MAS) with a mission to foster an open dialogue between the public and private sectors to advance FinTech in the digital economy.

The advisory committee comprises senior leaders from eight organizations ranging from established financial institutions to Tech/FinTech players. Mr. Chen Leiming, Senior Vice President, who is responsible for Ant Group’s international public policy and government affairs, serves as the representative of Ant Group. Mr. Chen also oversees the legal, compliance, AML and privacy functions of Ant Group’s international businesses.

As an advisory committee member, Mr. Chen Leiming will represent Ant Group and involve in providing strategic guidance on:

  1. galvanising global conversations to shape FinTech industry agendas worldwide;
  2. identifying key structural trends and issues shaping the future of financial services; and
  3. fostering an open dialogue between policymakers and FinTech players on Fintech risks and opportunities.

Speaking on the appointment of Ant Group as an advisory committee member, Mr. Sopnendu Mohanty, Chairman of Elevandi’s Board of Directors and Chief FinTech Officer of MAS, said: “Elevandi's mission is to bring together the public and private sector to adopt technology and build the future of finance that is inclusive, impactful and sustainable. We welcome organisations that have shown passion and dedication in harnessing FinTech for the growth and development of the new digital economy to participate as advisory committee members.”

Mr. Chen Leiming, Senior Vice President, Ant Group, said: “It is a great honour to represent Ant Group and contribute to the mission of Elevandi which we share and resonate deeply. At Ant Group, we are committed to leveraging technology and knowledge to provide inclusive services to those unserved and underserved, and contribute to the society through initiatives such as Ant Forest to promote low carbon lifestyle, and 10x1000 Tech for Inclusion to bridge the global digital skills gap."

"We look forward to joining the fellow members of the advisory committee in furthering Elevandi’s efforts on cultivating a more inclusive, green, and sustainable fintech landscape for the future," Mr. Chen said.

As part of Ant Group’s participation in Elevandi, Mr. Douglas Feagin, Senior Vice President for Global Strategic Partnerships and Investments at Ant Group will attend Elevandi’s inaugural Point Zero Forum in Zurich as a speaker. Point Zero Forum is an invite-only, in-person gathering to frame new ideas in Web 3.0 and sustainable finance; develop new regulatory frameworks; and provide access to investment capital.

For more information on Elevandi and the full list of advisory committee members, please visit https://www.elevandi.io/media/company-set-up-by-mas-to-advance-fintech-announces-advisory-committee .

About Ant Group

Ant Group aims to create the infrastructure and platform to support the digital transformation of the service industry. It strives to enable all consumers and small and micro businesses to have equal access to financial and other services that are inclusive, green and sustainable.

Ant Group is the owner and operator of Alipay, the leading digital platform in China serving hundreds of millions of users, and connecting them with merchants and partner financial institutions that offer inclusive financial services and digital daily life services such as food delivery, transport, entertainment, and healthcare.

Ant Group has further introduced Alipay+, which provides global cross-border mobile payments and marketing solutions that connect merchant partners, especially small and medium-sized businesses, with mobile payments and other payment methods, for them to better serve their users and customers from all over the world.

For more information, please visit our website at www.antgroup.com or follow us on Twitter @AntGroup.

About Elevandi

Elevandi is set up by the Monetary Authority of Singapore (MAS) to foster an open dialogue between the public and private sectors to advance FinTech in the digital economy. We work closely with governments, founders, investors, and corporate leaders to drive collaboration, education, and new sources of value at the industry and national levels. Our initiatives have convened over 300,000 people since 2016 to drive the growth of FinTech through events, closed-door roundtables, investor programmes, educational initiatives, and research. ​​

We have built a coordinated set of consequential products that drive activity at the industry, national, regional and global level, which include:

  • Singapore FinTech Festival (2-4 Nov 2022) , our annual flagship event for the global FinTech community.
  • Point Zero Forum (21-23 June 2022), our invite only collaboration with the Switzerland government to convene leaders, investors and founders in Zurich.
  • Elevandi Connects (7 July 2022), our programme and initiative to bring together early stage start-ups with leading investors and corporates to maximise commercial success in forging investment deals, co-innovation opportunities, and business partnerships.
  • World FinTech Festival (July-Nov 2022), our partnerships with the public and private sectors in markets around the world.
  • Green Shoots Series, our monthly event meetup which serves as a platform for public and private sector announcements and to discuss critical issues and opportunities in FinTech and the digital economy.
  • Education initiatives, our certificates and mentoring programmes to upskill and reskill the global FinTech community in collaboration with Oxygen by APIX, academic and industry partners.
  • Elevandi Forums, our purpose-driven roundtables aimed at bringing the public and private sectors together to advance developments and issues within the FinTech industry.
  • Elevandi FinTech Insider Report , our reports on digital advancements for the global FinTech industry which synthesise knowledge from our activities with the public and private sectors.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press release

- Vertex is on track for the U.S. FDA Prescription Drug User Fee Act (PDUFA) date of November 30 for potential accelerated approval of povetacicept –- Data published in NEJM and presented at ASN highlight povetacicept’s unique trifecta of efficacy, favorable safety, and the simplicity of dosing at-home every 4 weeks with a low-volume autoinjector –- Data presented at ASN include a qualitative study examining patient perspectives on current and emerging IgAN therapies, showing that 96% of participants preferred an autoinjector over a prefilled syringe, and 80% of participants preferred dosing every 4 weeks versus weekly dosing - - New clinical studies of povetacicept underway including a study evaluating patient experience on povetacicept administered via autoinjector - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Soc

BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press release

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 monthsTEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne,

Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:10:00 CEST | Press release

Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com

inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press release

Collaboration will establish the roadmap for bringing Pony.ai robotaxis to Kazakhstan on the inDrive ride-hailing platform, leveraging the NVIDIA Hyperion and the NVIDIA Halos safety system. inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a lea

Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press release

Phase Ia BreAK CRC-001 at ESMO 2026: 43% of patients, all initially unresectable, became eligible for surgery Poster 1023P – Developmental Therapeutics Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by u

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye